(RTTNews) - Genentech, a member of the Roche Group (ROG.SW, RO.SW), said the Phase III MINISTONE-2 study with one-dose Xofluza, for the treatment of flu in otherwise healthy children aged one to less than 12 years old, met its primary endpoint, which evaluated the proportion of patients with adverse events up to study day 29. The trial also demonstrated the efficacy of Xofluza to be comparable to oseltamivir. Xofluza was also comparable to oseltamivir with respect to key secondary endpoints.
Separately, a Phase III BLOCKSTONE study showed preventive treatment with Xofluza after exposure to an infected household member, reduced the risk of people testing positive for the flu by 86 percent versus placebo.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.